Coeptis Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company focusing on advancing cell therapy platforms for various diseases, recently announced that it has successfully regained compliance with Listing Rule 5550(a)(2) of the Nasdaq Hearings Panel. The company had previously received a written notice from The Nasdaq Stock Market, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the closing bid price of its common stock staying below $1.00 per share for 30 consecutive business days.

On January 21, 2025, Coeptis Therapeutics Holdings, Inc. was informed by The Nasdaq Stock Market that it had regained compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. This development means that the company is now back in compliance with Nasdaq Listing Rule 5550(a)(2), effectively resolving the matter.

A press release issued by the company on January 22, 2025, highlighted the successful restoration of compliance with the Nasdaq Listing Rule 5550(a)(2). In the released statement, Coeptis’ Chief Executive Officer, Dave Mehalick, expressed gratitude to the Nasdaq Hearings Panel for the approval and emphasized that regaining compliance with Nasdaq’s listing standards marks a positive beginning to what is anticipated to be a pivotal year for Coeptis.

Coeptis Therapeutics Holdings, Inc., along with its subsidiaries, is dedicated to developing innovative cell therapy platforms for various medical conditions such as cancer, autoimmune diseases, and infectious diseases. The company has been actively engaged in advancing treatment paradigms and enhancing patient outcomes through its cutting-edge research and development initiatives.

The company’s therapeutic portfolio encompasses assets that aim to revolutionize cellular immunotherapy, including a clinical-stage natural killer cell therapy technology. Coeptis is committed to pushing the boundaries in the field of biopharmaceuticals and technology with collaborations and innovative research efforts.

Coeptis has also taken strategic steps towards operational enhancement by establishing a Technology Division, which integrates advanced technologies like AI-powered marketing software and robotic process automation tools to streamline business operations and boost overall efficiency.

Headquartered in Wexford, Pennsylvania, Coeptis Therapeutics Holdings, Inc. remains steadfast in its mission to operate within FDA regulations, ensuring that all activities are in line with the highest standards of compliance and patient care. For more information on Coeptis, interested parties can visit their website at https://coeptistx.com.

The press release also underlined the company’s forward-looking statements, emphasizing the potential risks and uncertainties associated with the biopharmaceutical industry. Coeptis has acknowledged potential challenges such as maintaining listing on the Nasdaq Capital Market, clinical trial outcomes, regulatory approvals, competition, and the impact of external factors like the global COVID-19 pandemic.

Investors are advised to review the company’s SEC filings for a detailed insight into the risks associated with Coeptis Therapeutics Holdings, Inc., and its operations. The company has reassured its commitment to providing updates on any significant developments or changes that may impact its future performance.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bull Horn’s 8K filing here.

Bull Horn Company Profile

Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brand sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.